- Home
- HOWL vs ASRT Comparison
HOWL vs ASRT Comparison
Compare HOWL & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- ASRT
- Stock Information
- Founded
- HOWL 2017
- ASRT 1995
- Country
- HOWL United States
- ASRT United States
- Employees
- HOWL N/A
- ASRT N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- ASRT Health Care
- Exchange
- HOWL Nasdaq
- ASRT Nasdaq
- Market Cap
- HOWL 62.4M
- ASRT 78.3M
- IPO Year
- HOWL 2021
- ASRT 1997
- Fundamental
- Price
- HOWL $1.24
- ASRT $0.73
- Analyst Decision
- HOWL Strong Buy
- ASRT Strong Buy
- Analyst Count
- HOWL 3
- ASRT 3
- Target Price
- HOWL $9.00
- ASRT $3.25
- AVG Volume (30 Days)
- HOWL 241.7K
- ASRT 299.2K
- Earning Date
- HOWL 03-11-2025
- ASRT 03-12-2025
- Dividend Yield
- HOWL N/A
- ASRT N/A
- EPS Growth
- HOWL N/A
- ASRT N/A
- EPS
- HOWL N/A
- ASRT N/A
- Revenue
- HOWL $1,885,000.00
- ASRT $125,763,000.00
- Revenue This Year
- HOWL $36.45
- ASRT N/A
- Revenue Next Year
- HOWL $296.58
- ASRT $1.84
- P/E Ratio
- HOWL N/A
- ASRT N/A
- Revenue Growth
- HOWL N/A
- ASRT N/A
- 52 Week Low
- HOWL $1.03
- ASRT $0.73
- 52 Week High
- HOWL $6.89
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- HOWL 44.53
- ASRT 33.19
- Support Level
- HOWL $1.18
- ASRT $0.74
- Resistance Level
- HOWL $1.29
- ASRT $0.83
- Average True Range (ATR)
- HOWL 0.10
- ASRT 0.04
- MACD
- HOWL 0.00
- ASRT -0.00
- Stochastic Oscillator
- HOWL 56.10
- ASRT 17.29
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.